Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).

Jason John LukeDaniel J OlsonJacob B AllredCarrie A StrandRiyue BaoYuanyuan ZhaTimothy CarllBrian W LabadieBruno R BastosMarcus O ButlerDavid HoggPamela N MunsterGary K Schwartz

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

MET/VEGFR blockade with cabozantinib demonstrated no improvement in PFS but an increase in toxicity relative to temozolomide/dacarbazine in metastatic uveal melanoma.

Keyphrases

squamous cell carcinoma
small cell lung cancer
open label
placebo controlled
double blind
metastatic renal cell carcinoma
skin cancer
oxidative stress
phase ii
phase iii
clinical trial
basal cell carcinoma
vascular endothelial growth factor
newly diagnosed
radiation therapy